{"id":"W4282937497","doi":"10.1158/1538-7445.am2022-ct572","title":"Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nuvo Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Carboplatin; Pemetrexed; Internal medicine; Oncology; Trastuzumab; Tolerability; Durvalumab; Lapatinib; Cancer; Lung cancer; Chemotherapy; Cisplatin; Nivolumab; Breast cancer; Immunotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001046357,0.001626571,0.001466298,0.0005231365,0.0003332321,0.001210563,0.001104589,0.00113322,0.006593812],"category_scores_gemma":[0.0006096854,0.0006641982,0.001154605,0.0004388501,0.0008911441,0.000717698,0.0003598339,0.003590556,0.001731149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001718278,"about_ca_system_score_gemma":0.00190731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002307851,"about_ca_topic_score_gemma":0.005594261,"domain_scores_codex":[0.9997715,0.00007219903,0.00001061611,0.00005039497,0.00003941426,0.00005581658],"domain_scores_gemma":[0.9996793,0.00003364248,0.00005376688,0.00002903899,0.00002957719,0.0001746647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5073661,0.1293476,0.00772711,0.001542255,0.002162246,0.0005264518,0.0005379609,0.007206176,0.1737804,0.001175676,0.01742288,0.151205],"study_design_scores_gemma":[0.6281161,0.3376315,0.01141407,0.00009043558,0.0005858818,0.0005109223,0.00009393093,0.003249016,0.01170786,0.0003360036,0.006211672,0.00005262359],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887075,0.001980426,0.0006502589,0.0006005839,0.0001432695,0.002444889,0.002028523,0.0002218448,0.003222661],"genre_scores_gemma":[0.9758714,0.002577054,0.00205458,0.001410136,0.0000907503,0.002511932,0.006537247,0.00007849844,0.008868473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006593812,"threshold_uncertainty_score":0.02205855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0972688980441431,"score_gpt":0.4678346401220942,"score_spread":0.3705657420779511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}